September 27, 2017 Lab Top-10 Licensing, IP, and Legal

Thermo Fisher Scientific to Participate in Capitol Hill Briefing on Precision Medicine Advancements

Thermo Fisher Scientific to Participate in Capitol Hill Briefing on Precision Medicine Advancements CARLSBAD, Calif., Sept. 27, 2017 /PRNewswire/ — Thermo Fisher Scientific, the world leader in serving science, today announced it will participate in a Capitol Hill briefing hosted by AdvaMedDx and LUNGevity Foundation to discuss leading developments in medical diagnostics that are shaping... Read more

September 27, 2017 Atomic Spectroscopy Licensing, IP, and Legal M&A, Partnerships Microscopy

CHU Sainte-Justine Research Center opens cutting-edge microscopy platform in partnership with Leica Microsystems

Left to right: Elke Küster-Schöck, Lianne Dale, Gilles Hickson, Graziella Di Cristo, Jacques L. Michaud, and Wayne England. This platform is the latest of Leica Microsystems’ partnerships with research facilities across the world dedicated to helping top academic institutions provide tools that accelerate scientific discovery. The platform houses 11 state-of-the-art imaging systems from simple epi-fluorescence... Read more

September 22, 2017 Bio/Pharma/CRO Licensing, IP, and Legal

Roche receives EU approval of TECENTRIQ® (atezolizumab) in a specific type of metastatic lung cancer and two types of metastatic bladder cancer

Basel, 22 September 2017 Roche receives EU approval of TECENTRIQ® (atezolizumab) in a specific type of metastatic lung cancer and two types of metastatic bladder cancer TECENTRIQ provides a new treatment option for people with previously treated locally advanced or metastatic non-small cell cancer (NSCLC) TECENTRIQ is a new treatment option for people with metastatic... Read more

September 22, 2017 Bio/Pharma/CRO Licensing, IP, and Legal

Roche receives EU approval of Gazyvaro for people with previously untreated advanced follicular lymphoma

Basel, 22 September 2017 Roche receives EU approval of Gazyvaro for people with previously untreated advanced follicular lymphoma Approval is based on phase III GALLIUM study results, which showed superior progression-free survival for Gazyva/Gazyvaro compared to MabThera/Rituxan Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission has approved Gazyvaro® (obinutuzumab) in combination... Read more

September 18, 2017 Licensing, IP, and Legal

Xylem to participate in the Cowen and Company 2nd Annual Industrial Innovation & Technology Summit

RYE BROOK, N.Y.–(BUSINESS WIRE)–Sep. 18, 2017– Xylem Inc. (NYSE:XYL), a leading global water technology company dedicated to solving the world’s most challenging water issues, announced today that its Senior Vice President and Chief Marketing Officer, Joseph Vesey, will participate in a panel discussion entitled, Water Panel – Maximizing Utility Across Municipal and Industrial Markets at... Read more